Leuprolide Dosing for Ovarian Function Suppression in Breast Cancer

Recommended Dosing Schedules

The National Comprehensive Cancer Network (NCCN) guidelines recommend leuprolide administration at 3.75–7.5 mg intramuscularly every 4 weeks or 11.25–22.5 mg intramuscularly every 12 weeks for a duration of 5 years (or minimum 2 years) for ovarian function suppression in premenopausal women with hormone receptor-positive breast cancer 1

The NCCN guidelines recommend administering leuprolide for 5 years as the optimal duration, based on the TEXT-SOFT trials showing sustained disease-free survival benefit with this timeframe 1, 2, 3
A minimum of 2 years is acceptable for patients who cannot tolerate the full 5-year course, supported by the ASTRRA trial demonstrating 8-year disease-free survival of 85.4% with 2 years of OFS plus tamoxifen versus 80.2% with tamoxifen alone (HR 0.67, 95% CI 0.51–0.87) 1, 2

The NCCN guidelines recommend reserving leuprolide for premenopausal women with high-risk features, including young age, high-grade tumors, lymph node involvement, and patients who received adjuvant/neoadjuvant chemotherapy and remained premenopausal 1, 3

The NCCN guidelines recommend combining leuprolide with endocrine therapy, including leuprolide + exemestane (or another aromatase inhibitor) for highest-risk patients, and leuprolide + tamoxifen as an alternative 1, 2, 3
The TEXT-SOFT trials demonstrated superior disease-free survival with exemestane plus OFS (92.8%) versus tamoxifen plus OFS (88.8%) at 5 years (HR 0.66, 95% CI 0.55–0.80, P<0.001) 2, 3

The NCCN guidelines recommend that premenopausal patients wishing to continue adjuvant endocrine therapy after stopping leuprolide should switch to tamoxifen rather than continuing an aromatase inhibitor, as ovarian function may resume 1, 2

The NCCN guidelines recommend monitoring estradiol levels prior to each leuprolide dose, particularly in women under age 45, using high-sensitivity assays to confirm adequate ovarian suppression 1
The NCCN guidelines recommend measuring estradiol and FSH/LH levels in specific scenarios, including women under 60 years who are amenorrheic ≤12 months before starting adjuvant endocrine therapy, after chemotherapy-induced amenorrhea, and after discontinuing tamoxifen +/- OFS 1

The NCCN guidelines recommend starting leuprolide according to a specific algorithm, including starting with chemotherapy, without chemotherapy, or with radiation 1

The NCCN guidelines recommend avoiding the use of leuprolide in postmenopausal women, as they should receive aromatase inhibitors or tamoxifen alone without ovarian suppression 1

The American Society of Clinical Oncology recommends that ovarian suppression (Lupron) be added to tamoxifen for 5 years in premenopausal women who received adjuvant/neoadjuvant chemotherapy and remained premenopausal, with a strength of evidence of high quality 4, 5, 6
The National Comprehensive Cancer Network recommends that ovarian suppression (Lupron) be added to tamoxifen for premenopausal women with high-risk features, such as young age, high-grade tumors, or lymph node involvement 7
Tamoxifen alone is recommended for low-risk premenopausal women who did not receive chemotherapy, with a 5-year disease-free survival rate of 95% 7, 4, 5

The American Society of Clinical Oncology strongly recommends that ovarian suppression be offered to all premenopausal women with hormone receptor-positive metastatic breast cancer in combination with hormone therapy, with high-quality evidence 8, 9
Ovarian suppression (Lupron) plus tamoxifen is preferred over tamoxifen alone for patients without prior hormone therapy 8, 9
For patients who relapse early (≤12 months) on adjuvant tamoxifen, switching to ovarian suppression plus an aromatase inhibitor is recommended 8

Leuprolide acetate 3.75 mg every 4 weeks (monthly) is a recommended dosing schedule, with a strength of evidence of high quality 4, 5, 6
Monitoring estradiol levels with high-sensitivity assay is recommended in premenopausal women treated with GnRH agonists, especially when combined with aromatase inhibitors 8, 9

The American Society of Clinical Oncology recommends that Lupron not be used with tamoxifen in postmenopausal women, as they should receive aromatase inhibitors or tamoxifen alone 10, 11
Tamoxifen should not be continued if disease recurs within 12 months, as this indicates resistance; switching to an aromatase inhibitor with continued ovarian suppression is recommended 8
Ovarian suppression should not be used in low-risk premenopausal patients who did not receive chemotherapy, as tamoxifen alone is highly effective (95% disease-free survival) 7